Avutometinib + Adagrasib for Lung Cancer
(RAMP204 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of two drugs, avutometinib (VS-6766) and adagrasib, in patients with a specific type of lung cancer who have not responded to previous treatments. The drugs aim to stop the cancer cells from growing by blocking the signals that tell them to multiply. Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.
Who Is on the Research Team?
MD Verastem
Principal Investigator
Verastem, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with a specific mutation in their lung cancer (KRAS G12C) who have tried but not responded to certain treatments. They should be relatively healthy, able to perform daily activities with ease, and must not have more than three previous cancer treatments or active infections like hepatitis or HIV.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
To determine the recommended phase 2 dose (RP2D) for VS-6766 in combination with adagrasib
Treatment Part B
To determine the efficacy of the RP2D identified from Part A
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Adagrasib
- Avutometinib (VS-6766)
Adagrasib is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Verastem, Inc.
Lead Sponsor
Mirati Therapeutics Inc.
Industry Sponsor
Dr. Charles M. Baum
Mirati Therapeutics Inc.
Chief Executive Officer since 2023
MD, PhD
Dr. Joseph Leveque
Mirati Therapeutics Inc.
Chief Medical Officer since 2021
MD